文献速递功能神经外科

苍白球内侧核与丘脑底核脑深部电刺激治疗Meige综合征:随机对照双盲多中心试验

Pallidus internus versus subthalamic nucleus deep brain stimulation for Meige syndrome: a randomized, controlled, double-blind multicenter trial.
PubMed 文献 · J Neurosurg · 2026-02-20

这项随机对照双盲多中心试验比较了GPi-DBS与STN-DBS治疗Meige综合征的安全性和疗效,62例患者随机分组各31例并完成1年随访。两组运动症状改善率、抑郁焦虑及生活质量无显著差异,GPi-DBS总电能量显著更高,不良事件率相当。GPi最佳刺激靶点为苍白球后外侧背侧,STN为丘脑底核背侧,术前言语/吞咽BFMDRS评分是DBS疗效的独立负性预测因素。

要点

  • STN-DBS所需刺激参数低于GPi-DBS,总电能量显著更少。
  • 术前言语/吞咽损害越重,DBS疗效越差,为独立负性预测因素。

核心结论

  • GPi-DBS与STN-DBS治疗Meige综合征在安全性和疗效上相当。
  • STN-DBS所需刺激参数低于GPi-DBS。
  • GPi最佳刺激靶点为苍白球后外侧背侧,STN最佳靶点为丘脑底核背侧。
  • 术前言语/吞咽BFMDRS评分越高,DBS疗效越差。

研究设计与样本

  • 随机、对照、双盲、多中心试验,共纳入62例Meige综合征患者。
  • 患者随机接受GPi-DBS(n=31)或STN-DBS(n=31),均完成1年随访。
  • 主要结局为BFMDRS运动功能改善,次要结局包括情绪、整体认知功能和生活质量。
  • 采用Lead-DBS探索DBS最佳刺激靶点。

主要发现

  • GPi-DBS组BFMDRS运动评分平均改善率在3、6、12个月分别为54.9%、57.3%、59.7%。
  • STN-DBS组相应改善率分别为57.1%、59.0%、59.9%。
  • 两组在运动症状、抑郁、焦虑及生活质量疗效上随访期间无显著差异。
  • GPi-DBS组总电能量显著高于STN-DBS组。
  • 不良事件率GPi-DBS组16.1%、STN-DBS组12.9%(p>0.99)。

关键数值与推荐

  • 主要疗效指标为BFMDRS运动评分改善率。
  • GPi-DBS组1年BFMDRS运动评分平均改善59.7%,STN-DBS组为59.9%。
  • 两组不良事件率分别为16.1%和12.9%(p>0.99)。
  • GPi-DBS靶点相关性ρ=0.76(p=0.001),STN-DBS靶点相关性ρ=0.66(p=0.005)。
  • 术前言语/吞咽BFMDRS评分为疗效负性预测因素(p=0.025)。

临床怎么用

  • GPi-DBS与STN-DBS均可作为Meige综合征的安全有效选择,可根据患者情况个体化选用。
  • 若考虑降低刺激参数和总电能量,STN-DBS可能更具优势。
  • 术前存在明显言语/吞咽损害者应告知DBS疗效可能较差。
  • GPi-DBS靶点可参考苍白球后外侧背侧,STN-DBS靶点可参考丘脑底核背侧。

局限性

  • 样本量62例,1年随访,长期疗效与安全性尚待验证。
  • 原文未报告盲法具体实施细节及多中心中心间差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The aim of this randomized, controlled, double-blind multicenter trial was to compare the safety and efficacy of globus pallidus internus (GPi) and subthalamic nucleus (STN) deep brain stimulation (DBS) in patients with Meige syndrome (MeS). Additionally, the authors explored the optimal site of DBS and identified predictors of clinical outcomes. METHODS: The primary outcome was improvement in motor function as assessed by the Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS). The secondary outcomes included mood, global cognitive function, and quality of life (QOL). The optimal stimulation site for DBS was investigated using Lead-DBS. RESULTS: A total of 62 patients with MeS were randomized to receive GPi-DBS (n = 31) or STN-DBS (n = 31), and all completed the 1-year follow-up. In the GPi-DBS group, the mean improvement rates in BFMDRS movement scores were 54.9%, 57.3%, and 59.7% at 3, 6, and 12 months, respectively. In the STN-DBS group, the corresponding rates were 57.1%, 59.0%, and 59.9%. There was no significant difference in the efficacy of motor symptoms, depression, anxiety, and QOL between the two groups during follow-up. The total electrical energy delivered in the GPi-DBS group was significantly greater than that in the STN-DBS group. The adverse event rates were comparable between the GPi-DBS (16.1%) and STN-DBS (12.9%) groups (p > 0.99). The "sweet spot" for GPi-DBS was found to be located in the posterolateral dorsal pallidum (ρ = 0.76, p = 0.001), while the sweet spot for STN-DBS was found to be situated in the dorsal subthalamic nucleus (ρ = 0.66, p = 0.005). Preoperative BFMDRS movement subscores for speech/swallowing were identified as an independent predictor negatively associated with DBS efficacy (p = 0.025). CONCLUSIONS: GPi-DBS and STN-DBS demonstrate comparable safety and efficacy in patients with MeS. STN-DBS requires lower stimulation parameters than GPi-DBS. The optimal stimulation sites are the posterolateral dorsal GPi and the dorsal STN. Greater preoperative speech/swallowing impairment predicts poorer outcomes.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Wu Y, Ren HB, Xiong BT, et al. Pallidus internus versus subthalamic nucleus deep brain stimulation for Meige syndrome: a randomized, controlled, double-blind multicenter trial. J Neurosurg. 2026. PMID: 41719550. doi:10.3171/2025.9.JNS251188

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。